News from PipelinereviewFollowNews from PipelinereviewStay current with all the latest and breaking news from Pipelinereview. Compare headlines and media bias behind news outlets on stories breaking today.Ground News has come across 216 headlines reported on by Pipelinereview during the past 3 months. Ground News rates Pipelinereview’s media bias as unknown. Ground News is unable to assign a bias rating and does not have ratings available from Ad Fontes Media, All Sides, and Media Bias/Fact Check. Pipelinereview’s factuality rating is unknown. Ground News calculates this rating using a combination of the fact and reliability ratings from Ad Fontes Media and Media Bias/Fact Check.Follow Stay current with all the latest and breaking news from Pipelinereview. Compare headlines and media bias behind news outlets on stories breaking today. Ground News has come across 216 headlines reported on by Pipelinereview during the past 3 months. Ground News rates Pipelinereview’s media bias as unknown. Ground News is unable to assign a bias rating and does not have ratings available from Ad Fontes Media, All Sides, and Media Bias/Fact Check. Pipelinereview’s factuality rating is unknown. Ground News calculates this rating using a combination of the fact and reliability ratings from Ad Fontes Media and Media Bias/Fact Check. Information about PipelinereviewWhere is Pipelinereview located?Pipelinereview's WebsiteMedia Bias RatingsDo you diasgree? Edit biasLearn more about Media Bias Ratings.FactualityAverage Factuality Rating: UnknownLearn more about Factuality Ratings.Top Pipelinereview NewsBusiness · United StatesFDA approves Bristol Myers Squibb’s schizophrenia drug, the first new type of treatment in decades50% Center coverage: 30 sourcesThe Food and Drug Administration on Thursday approved Bristol Myers Squibb’s highly anticipated schizophrenia drug Cobenfy, the first novel type of treatment for the debilitating, chronic mental disorder in more than seven decades. See the StoryPfizerPfizer withdraws sickle cell disease treatment from all markets75% Center coverage: 4 sourcesU.S. drugmaker Pfizer said on Wednesday it is withdrawing its sickle cell disease therapy Oxbryta in all markets where it is approved and discontinuing all studies and access programs related to the treatment.See the StoryStock Markets · United StatesDupixent® (dupilumab) Approved in China as the First-ever Biologic Medicine for Patients with Chronic Obstructive Pulmonary Disease (COPD) - Regeneron Pharmaceuticals (NASDAQ:REGN)67% Center coverage: 3 sourcesApproval follows EU approval of Dupixent for adults with COPD with raised blood eosinophils, and is based on two landmark Phase 3 trials showing Dupixent significantly reduced exacerbations, improved lung function and also improved health-related quality of life COPD is the most prevalent chronic respiratory disease in China, and is a priority within the government's Healthy China 2030 public health plan Dupixent is now approved in four indicat…See the StoryLatest News StoriesTopics Most Covered by pipelinereviewVaccinesCoronavirusAstraZenecaEuropean UnionMerckVaccinesCoronavirusAstraZenecaSources Covering Similar Topicsstocktitan.netClinical Trials ArenaPharmacy TimesEndpoints NewsGreen Stock Newsstocktitan.netClinical Trials ArenaPharmacy TimesSuggest a sourceLooking for a source we don't already have? Suggest one here.You've scrolled to the bottom of the feed, there are no more stories.Breaking News Topics Related to PipelinereviewMassachusettsChinaMiddlesex County, MassachusettsCalifornia, United StatesCambridge, MassachusettsMarylandUnited States